Literature DB >> 27055959

The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population.

Moon Hee Yang1, Jidong Sung2, Geum-Youn Gwak3.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is associated with a higher risk of cardiovascular disease, but the relationship has not been established in nonobese populations. Higher apolipoprotein B (apo B) levels and the apo B/A1 ratio and lower apo A1 levels are associated with an elevated risk of cardiovascular disease. We investigated the associations between apo B, apo A1, and the apo B/A1 ratio and the presence of metabolic syndrome and NAFLD in both normal-weight and overweight Koreans.
METHODS: This cross-sectional study consisted of 8327 consecutive both normal-weight and overweight Koreans with NAFLD diagnosed by ultrasonography at the Samsung Medical Center in Korea from January 2008 to December 2010.
RESULTS: The prevalence of NAFLD was 27.1% among the 8327 participants. Higher serum triglyceride levels and the apo B/A1 ratio and lower high-density lipoprotein cholesterol and apo A1 levels were significantly associated with higher prevalence of metabolic syndrome in both normal-weight group and overweight group. The multivariate-adjusted odds ratios (ORs) for NAFLD in normal-weight group after comparing the fourth vs the first quartiles of the triglyceride, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, apo B, apo A1, and the apo B/A1 ratio data were 2.89 (95% confidence interval [CI], 2.19-3.83; P trend < .001), 0.60 (95% CI, 0.46-0.78; P trend < .001), 1.67 (95% CI, 1.33-2.11; P trend < .001), 1.88 (95% CI, 1.48-2.39; P trend < .001), 0.73 (95% CI, 0.58-0.93; P trend < .001), and 1.86 (95% CI, 1.45-2.38; P trend < .001), respectively. The corresponding adjusted ORs in the overweight group were 3.43 (95% CI, 2.60-4.54; P trend < .001), 0.89 (95% CI, 0.68-1.16; P trend = .221), 1.41 (95% CI, 1.11-1.78; P trend = .001), 1.58 (95% CI, 1.21-2.06; P trend < .001), 0.99 (95% CI, 0.77-1.27; P trend = .958), and 1.53 (1.16-2.01; P trend = .002), respectively.
CONCLUSIONS: Higher serum triglyceride, LDL cholesterol, apo B1 levels, and the apo B/A1 ratio were significantly associated with NAFLD independent of metabolic syndrome in both normal-weight and overweight Koreans. Lower serum HDL cholesterol and apo A1 levels were related to NAFLD in normal-weight participants. Our results suggest that the presence of NAFLD may be associated with increased risk for coronary artery disease in both normal-weight and overweight Koreans.
Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apolipoprotein A1; Apolipoprotein B; Apolipoprotein B/A1 ratio; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2015        PMID: 27055959     DOI: 10.1016/j.jacl.2015.11.017

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  14 in total

Review 1.  Nonalcoholic fatty liver disease: implications for cardiovascular risk.

Authors:  Amreen Dinani; Arun Sanyal
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

2.  Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Keyvan Heydari; Mohammad Yousefi; Reza Alizadeh-Navaei; Parisa Lotfi; Fateme Sheydaee; Maedeh Raei; Alireza Vahdatinia; Amirhossein Hessami; Sajjad Rafati; Mahmood Moosazadeh; Roya Ghasemian; Fatemeh Salehi; Haleh Massoudi; Fatemeh Ghaffari-Saravi; Sahar Rismantab
Journal:  Turk J Gastroenterol       Date:  2022-03       Impact factor: 1.555

3.  Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.

Authors:  Chan Joo Lee; Yunbeom Lee; Sungha Park; Seok-Min Kang; Yangsoo Jang; Ji Hyun Lee; Sang-Hak Lee
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

4.  Association of sleep duration with apolipoproteins and the apolipoprotein B/A1 ratio: the China health and nutrition survey.

Authors:  Huihui Ren; Zhelong Liu; Xinrong Zhou; Gang Yuan
Journal:  Nutr Metab (Lond)       Date:  2018-01-05       Impact factor: 4.169

5.  Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study.

Authors:  Tian Jiang; Xia Chen; Chenmei Xia; Huamin Liu; Haifan Yan; Guoping Wang; Zhongbiao Wu
Journal:  Sci Rep       Date:  2019-03-19       Impact factor: 4.379

6.  Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.

Authors:  Yu Zhang; He He; Yu-Ping Zeng; Li-Dan Yang; Dan Jia; Zhen-Mei An; Wei-Guo Jia
Journal:  Lipids Health Dis       Date:  2020-06-11       Impact factor: 3.876

7.  Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.

Authors:  Hangkai Huang; Jinghua Wang; Lei Xu; Min Miao; Chengfu Xu
Journal:  Int J Endocrinol       Date:  2021-06-04       Impact factor: 3.257

8.  Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome.

Authors:  Chen Chen; Caiyun Zhang; Xuelin Wang; Feijuan Zhang; Ze Zhang; Pengchai Ma; Shuzhi Feng
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-07       Impact factor: 2.586

9.  Association between ratio of γ-glutamyl transpeptidase to high-density lipoprotein cholesterol and prevalence of nonalcoholic fatty liver disease and metabolic syndrome: a cross-sectional study.

Authors:  Guofang Feng; Limin Feng; Ying Zhao
Journal:  Ann Transl Med       Date:  2020-05

Review 10.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.